Stock Track | Definium Therapeutics Soars 5.24% Intraday on Analyst Buy Rating and $26 Price Target

Stock Track03-04

Definium Therapeutics' stock surged 5.24% during intraday trading on Tuesday, following a positive analyst update.

The movement comes after Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on the company and set a price target of $26.00, signaling confidence in the stock's future performance.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment